Betta Pharmaceuticals Co (SZSE:300558) Net Income From Continuing Operations : ¥379 Mil (TTM As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Betta Pharmaceuticals Co Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Betta Pharmaceuticals Co's net income from continuing operations for the three months ended in Mar. 2024 was ¥94 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Mar. 2024 was ¥379 Mil.

Betta Pharmaceuticals Co Net Income From Continuing Operations Historical Data

The historical data trend for Betta Pharmaceuticals Co's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Betta Pharmaceuticals Co Net Income From Continuing Operations Chart

Betta Pharmaceuticals Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Income From Continuing Operations

Get a 7-Day Free Trial

225.84

601.09

379.56

124.76

333.62

Betta Pharmaceuticals Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net Income From Continuing Operations	Get a 7-Day Free Trial															47.94	93.64	152.55	39.49	93.79

Betta Pharmaceuticals Co Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥379 Mil.

Betta Pharmaceuticals Co (SZSE:300558) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Betta Pharmaceuticals Co Ltd (SZSE:300558) » Definitions » Net Income From Continuing Operations

Traded in Other Exchanges

N/A

Address

No.355, Xingzhong Road, Yuhang Economic and Technological Development Zone, Zhejiang Province, Hangzhou, CHN

Website

http://www.bettapharma.com

Betta Pharmaceuticals Co Ltd is a hi-tech pharmaceutical enterprise focuses on research and development of innovative medicines. The company's drug is used for various diseases such as malignant tumors, diabetes, and cardio-cerebrovascular disease. Further, it offers Icotinib hydrochloride, an orally administered small-molecule and a reversible tyrosine kinase inhibitor, which is used for the treatment of non-small-cell lung cancer. Geographically, the group operates through China.

Executives

Wang Jia Bing	Directors, executives
Ding Lie Ming	Directors, executives
Cai Wan Yu	Executives

Betta Pharmaceuticals Co (SZSE:300558) Headlines

No Headlines